1. Home
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Amyloid beta-protein inhibitors - Pipeline Insight, 2022

Amyloid beta-protein inhibitors - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6068395
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Amyloid Beta-Protein Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Amyloid Beta-Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Amyloid Beta-Protein Inhibitors Understanding

Amyloid Beta-Protein Inhibitors: Overview
Amyloid-? (A?) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer’s disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield A?. Amyloid-? molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-? peptide is due to overproduction of A? and/or the failure of clearance mechanisms. Amyloid-? self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels.

Function – The progressive production and subsequent accumulation of ?-amyloid (A?), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer’s disease (AD). A? is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of A? culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains.

Amyloid Beta-Protein Inhibitors- Inhibition of the formation of these toxic polymers of A? has thus emerged as an approach to developing therapeutics for AD. Therefore, blocking the initial stages of A? peptide aggregation with small molecules could hold considerable promise as the starting point for the development of new therapies for AD.

Amyloid Beta-Protein Inhibitors Emerging Drugs Chapters
This segment of the Amyloid Beta-Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Amyloid Beta-Protein Inhibitors Emerging Drugs
• Aducanumab: Biogen
Biogen’s aducanumab — a monoclonal antibody is currently under review by the U.S. Food and Drug Administration. If ultimately approved, it is predicted that the drug, which only showed modest efficacy in phase III clinical trial, could become the best-selling drug of all time.

• Crenezumab: Hoffman-La-Roche
Crenezumab (RG7412) is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the main constituent of amyloid plaque in the brains of patients with Alzheimer’s disease and is proposed to be causative in the development of the disease. A phase II clinical trial is evaluating Crenezumab in healthy individuals with a history of familial Alzheimer’s disease. Roche plans to submit regulatory applications for marketing Crenezumab for Alzheimer’s disease by 2023.
Further product details are provided in the report……..

Amyloid Beta-Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Amyloid Beta-Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Amyloid Beta-Protein Inhibitors
There are approx. 10+ key companies which are developing the Amyloid Beta-Protein Inhibitors. The companies which have their Amyloid Beta-Protein Inhibitors drug candidates in the most advanced stage, i.e. preregistration include Biogen.
• Phases
This report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Amyloid Beta-Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Amyloid Beta-Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyloid Beta-Protein Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid Beta-Protein Inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Amyloid Beta-Protein Inhibitors R&D.
• The therapies under development are focused on novel approaches for Amyloid Beta-Protein Inhibitors.

Amyloid Beta-Protein Inhibitors Report Insights
• Amyloid Beta-Protein Inhibitors Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Amyloid Beta-Protein Inhibitors Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Amyloid Beta-Protein Inhibitors drugs?
• How many Amyloid Beta-Protein Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Amyloid Beta-Protein Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyloid Beta-Protein Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Amyloid Beta-Protein Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Amyotrophic Lateral Sclerosis Treatment Market Research Report by Treatment, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • $ 3949
  • October 2022
  • 223 pages

Amyotrophic Lateral Sclerosis Treatment Market Research Report by Treatment, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 The Global Amyotrophic Lateral Sclerosis ...

  • World
  • Dementia
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on